These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

702 related articles for article (PubMed ID: 7523719)

  • 1. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C).
    Epstein JI; Walsh PC; Brendler CB
    J Urol; 1994 Nov; 152(5 Pt 2):1721-9. PubMed ID: 7523719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
    Epstein JI; Walsh PC; Carmichael M; Brendler CB
    JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate.
    Carter HB; Sauvageot J; Walsh PC; Epstein JI
    J Urol; 1997 Jun; 157(6):2206-9. PubMed ID: 9146616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy.
    Sebo TJ; Bock BJ; Cheville JC; Lohse C; Wollan P; Zincke H
    J Urol; 2000 Jan; 163(1):174-8. PubMed ID: 10604340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.
    Epstein JI; Chan DW; Sokoll LJ; Walsh PC; Cox JL; Rittenhouse H; Wolfert R; Carter HB
    J Urol; 1998 Dec; 160(6 Pt 2):2407-11. PubMed ID: 9817393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics.
    Noguchi M; Stamey TA; Neal JE; Yemoto CE
    J Urol; 2000 Jun; 163(6):1751-5. PubMed ID: 10799175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do clinically insignificant tumors of the prostate exist?
    Stamatiou K; Alevizos A; Mariolis A; Spiliopoulou C; Alevizou A; Bovis K; Sofras F
    Urol Int; 2008; 81(4):379-82. PubMed ID: 19077395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer.
    Epstein JI; Walsh PC; Sauvageot J; Carter HB
    J Urol; 1997 Nov; 158(5):1886-90. PubMed ID: 9334623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.
    Freedland SJ; Csathy GS; Dorey F; Aronson WJ
    J Urol; 2002 Feb; 167(2 Pt 1):516-20. PubMed ID: 11792909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease.
    Helfand BT; Mongiu AK; Kan D; Kim DY; Loeb S; Roehl KA; Meeks JJ; Smith ND; Catalona WJ
    BJU Int; 2009 Aug; 104(3):304-9. PubMed ID: 19239451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome.
    Feneley MR; Gillatt DA; Hehir M; Kirby RS
    Br J Urol; 1996 Dec; 78(6):911-8; discussion 919-20. PubMed ID: 9014719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers.
    Noguchi M; Stamey TA; McNeal JE; Nolley R
    J Urol; 2003 Aug; 170(2 Pt 1):459-63. PubMed ID: 12853799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes.
    Stamey TA; Donaldson AN; Yemoto CE; McNeal JE; Sözen S; Gill H
    J Urol; 1998 Dec; 160(6 Pt 2):2412-7. PubMed ID: 9817394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final pathohistology after radical prostatectomy in patients eligible for active surveillance (AS).
    Lellig E; Gratzke C; Kretschmer A; Stief C
    World J Urol; 2015 Jul; 33(7):917-22. PubMed ID: 26047652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.